US74766Q1013
© BusinessWire
22.12.2025
QTRX
LISTED
NASDAQ
Quanterix Announces Landmark Nature Study Redefining Alzheimer’s Disease Neuropathology Prevalence
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the prestigious journal Nature. The study, which utilized Quanterix’s ultra-sensitive Simoa p-Tau 217 (phosphorylated tau at threonine 217) research assay,...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2025
QTRX
LISTED
NASDAQ
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
News Preview
Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company’s next phase of growth. These changes include the appointment of two highly...
Themefolio
Profiler
Peergroup
© BusinessWire
17.11.2025
QTRX
LISTED
NASDAQ
Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the publication of a landmark study in the high-impact journal Brain. The paper validates that multiplexed Simoa assays for Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Cha...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
10.11.2025
QTRX
LISTED
NASDAQ
Quanterix Releases Financial Results for the Third Quarter of 2025
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the third quarter ended September 30, 2025.
“During the third quarter, we delivered on our revenue expectations despite challenging market conditions,” said Masoud To...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
03.11.2025
QTRX
LISTED
NASDAQ
Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, November 10, 2025, at 4:30 p.m. E.T., to discuss its third quarter 2025 financial results.
Quanterix will issue a press release regarding its third quarter 2025 fi...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2025
QTRX
LISTED
NASDAQ
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker re...
Themefolio
Profiler
Peergroup
© BusinessWire
28.07.2025
QTRX
LISTED
NASDAQ
Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the first to market, commercial launch of two novel phospho-tau assays: p‑Tau 205 and p‑Tau 212, expanding its market-leading portfolio of blood-based biomarkers for Alzheimer’s disease and neurodegeneration. The...
Themefolio
Profiler
Peergroup
© BusinessWire
11.07.2025
QTRX
LISTED
NASDAQ
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units (“RSUs”) representing 267,269 shares of Quanterix common stock to twenty employees newly-hire...
Themefolio
Profiler
Peergroup
© BusinessWire
08.07.2025
QTRX
LISTED
NASDAQ
Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum
News Preview
Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology an...
Themefolio
Profiler
Peergroup
© BusinessWire
23.06.2025
QTRX
LISTED
NASDAQ
Quanterix Expands Reach with IVD and Large Reference Labs
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration by the Ministry of Food and Drug Safety (MFDS) in South Korea through its regional distribution partner, HS Biosystems....
Themefolio
Profiler
Peergroup
© PR Newswire
11.06.2025
QTRX
LISTED
NASDAQ
Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders
News Preview
RINCON, Puerto Rico, June 11, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), today issued the following statement condemning the Company's failure thus far to schedule its 2025 Annual Meeting on time.
"Quan...
Themefolio
Profiler
Peergroup
© BusinessWire
06.06.2025
QTRX
LISTED
NASDAQ
Quanterix to Present at Goldman Sachs Global Healthcare Conference
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
12.05.2025
QTRX
LISTED
NASDAQ
Quanterix Releases Financial Results for the First Quarter of 2025
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025.
"During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving fo...
Themefolio
Profiler
Peergroup
© BusinessWire
05.05.2025
QTRX
LISTED
NASDAQ
Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, May 12, 2025, at 4:30 p.m. E.T., to discuss its first quarter 2025 financial results.
Quanterix will issue a press release regarding its first quarter 2025 financia...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
QTRX
LISTED
NASDAQ
Kent Lake Issues Statement on Quanterix’s Blatant Disregard for Will of Shareholders
News Preview
Kent Lake PR LLC (“Kent Lake”), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today issued the following statement regarding the Company’s announcement of an amended merger agreement (the “Amended Merger Agreement”) related to its proposed merger (the “Merger”...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
QTRX
LISTED
NASDAQ
Quanterix and Akoya Biosciences Announce Amended Merger Agreement
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced an amendment to the terms of their previously announced merger agreement.
Under the amended terms, Quanterix will issue approximately 7.76 mil...
Themefolio
Profiler
Peergroup
© BusinessWire
17.04.2025
QTRX
LISTED
NASDAQ
Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders
News Preview
Kent Lake PR LLC (“Kent Lake”), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) and sent a letter to its fellow Quanterix shareholders in...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
QTRX
LISTED
NASDAQ
Kent Lake Comments on Quanterix’s Value Destructive Bridge Financing for Financially Troubled Akoya
News Preview
Kent Lake PR LLC (“Kent Lake”) is a holder of approximately 7.5% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX). Today, Kent Lake issued a statement related to recent disclosures indicating that Quanterix has officially entered into a Securities Purchase Agreement under which Akoya Bioscience...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
QTRX
LISTED
NASDAQ
Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the inclusion of a new dried blood spot extraction (DBS) kit as part of their industry-leading Simoa® assay kits at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Di...
Themefolio
Profiler
Peergroup
© BusinessWire
17.03.2025
QTRX
LISTED
NASDAQ
Quanterix Releases Financial Results for the Fourth Quarter of 2024
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024.
“During the fourth quarter, we delivered 11% revenue growth, our seventh straight quarter of double-digit growth, despite a capital constrained...
Themefolio
Profiler
Peergroup
© BusinessWire
17.03.2025
QTRX
LISTED
NASDAQ
Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today’s Earnings Call
News Preview
Kent Lake PR LLC (“Kent Lake”) is a holder of 7.47% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX). Kent Lake has previously issued a public presentation detailing its opposition to the Company’s proposed transaction (the “Transaction”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA), and has...
Themefolio
Profiler
Peergroup
© BusinessWire
13.03.2025
QTRX
LISTED
NASDAQ
Quanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, March 17, 2025, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2024 financial results.
Quanterix will issue a press release regarding fourth quarter...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
QTRX
LISTED
NASDAQ
Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix’s Proposed Merger with Akoya Biosciences
News Preview
Kent Lake PR LLC (“Kent Lake”) a holder of 7.25% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today issued a presentation to Quanterix shareholders in connection to Kent Lake’s opposition to the Company’s proposed transaction (the “Transaction”) with Akoya Biosciences (“Akoya”) (NASDAQ: AK...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
QTRX
LISTED
NASDAQ
Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board
News Preview
Kent Lake PR LLC (“Kent Lake”), a holder of 6.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), announced today it has nominated three highly qualified, independent candidates for election to the Company’s Board of Directors (the “Board”) at the 2025 Annual Meeting of Shareholders (the “Annu...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
QTRX
LISTED
NASDAQ
Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition
News Preview
Quanterix Corporation (NASDAQ: QTRX) (“Quanterix” or the “Company”), a company fueling scientific discovery through ultra-sensitive biomarker detection, today reiterated the strategic and financial benefits of its proposed acquisition of Akoya Biosciences, which will create the first integrated solution for ultra-sensitive detection of blood- and...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
QTRX
LISTED
NASDAQ
Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company’s Proposed Merger with Akoya Biosciences
News Preview
Kent Lake PR LLC (“Kent Lake”), a holder of 5.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today highlighted its opposition to the Company’s proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA). Kent Lake has also issued an open letter to all Quanterix sharehol...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
QTRX
LISTED
NASDAQ
Quanterix Provides Update on Financial Performance
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced selected preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.
“I am pleased with our team’s execution as we delivered our seventh consecutive quarter of double-digit reve...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
QTRX
LISTED
NASDAQ
QTRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Quanterix Corporation Is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Quanterix Corporation (NASDAQ: QTRX) and Akoya Biosciences, Inc. is fair to Quanterix shareholders. Upon completion of the proposed transaction, Quanterix shareholders will own approximately 70% of the combined company.
Halper Sadeh encourages Quanterix shareho...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
QTRX
LISTED
NASDAQ
Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction. The transaction will create the first integ...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
QTRX
LISTED
NASDAQ
David R. Walt Receives National Medal of Technology and Innovation
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that David R. Walt, co-inventor of the Company’s Simoa technology has received the National Medal of Technology and Innovation, bestowed by the President of the United States.
Since it was first awarded in 1985...
Themefolio
Profiler
Peergroup
© BusinessWire
02.01.2025
QTRX
LISTED
NASDAQ
Quanterix to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13th-16th at the Westin St. Francis Hotel in San Francisco, CA. Quan...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
QTRX
LISTED
NASDAQ
Quanterix Expands Capabilities with Strategic Acquisition of EMISSION
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the acquisition of EMISSION iNC. (“EMISSION”). Quanterix expects the transaction will close in January 2025.
“As we expand our technology stack toward higher multi-plex and multi-om...
Themefolio
Profiler
Peergroup
© BusinessWire
22.11.2024
QTRX
LISTED
NASDAQ
Quanterix Announces Receipt of Expected Notice from Nasdaq
News Preview
Quanterix Corporation (NASDAQ: QTRX) today announced that it received a notice (the “Notice”) on November 21, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Form 10-Q"), it is no longer in compliance with Nasdaq Lis...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
QTRX
LISTED
NASDAQ
Rosen Law Firm Encourages Quanterix Corporation Investors to Inquire About Securities Class Action Investigation – QTRX
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Quanterix Corporation (NASDAQ: QTRX) resulting from allegations that Quanterix may have issued materially misleading business information to the investing public.
So What: If you purchased Quanterix secur...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
QTRX
LISTED
NASDAQ
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Quanterix Corporation (QTRX) on Behalf of Investors
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX) investors concerning the Company’s possible violations of federal securities laws.
On November 12, 2024, after market hours, Quanterix disclosed that it had “identified an error related to the capitalization...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
QTRX
LISTED
NASDAQ
QTRX Investors Have Opportunity to Join Quanterix Corporation Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation (“Quanterix” or “the Company”) (NASDAQ: QTRX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
QTRX
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Quanterix Corporation (QTRX) on Behalf of Investors
News Preview
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX) investors concerning the Company’s possible violations of the federal securities laws.
If you suffered a loss on your Quan...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
QTRX
LISTED
NASDAQ
The Law Offices of Frank R. Cruz Announces Investigation of Quanterix Corporation (QTRX) on Behalf of Investors
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ:QTRX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On November 12, 2024, after market hours, Quan...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
QTRX
LISTED
NASDAQ
Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced preliminary financial results for the third quarter ended September 30, 2024 and reaffirmed its full year 2024 guidance. The Company also disclosed the need to restate certain prior period financial statements t...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
QTRX
LISTED
NASDAQ
Quanterix To Report Third Quarter 2024 Financial Results on November 12, 2024
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Tuesday, November 12, 2024, at 4:30 p.m. E.T., to discuss third quarter 2024 financial results.
Quanterix will issue a press release regarding third quarter 2024 financial...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2024
QTRX
LISTED
NASDAQ
New Multi-Marker Blood Test from Lucent Diagnostics Increases the Number of Patients Receiving Early Alzheimer’s Disease Diagnostic Information
News Preview
Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker blood test designed to help detect Alzheimer’s Disease (AD) in a broader range of patients.
Recent Alzheimer’s Association criteria for diagnosing Alzheimer’s recommend that plasma p-Tau 217 tests be designed with two cutoffs...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2024
QTRX
LISTED
NASDAQ
Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors.
Dr. Magovčević-Liebisch brings more than 25 years of biopharmaceutical industry experience, inclu...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2024
QTRX
LISTED
NASDAQ
Quanterix Announces Commercialization of p-Tau 217 Test Kit
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it is making its Simoa® p-Tau 217 Planar Kit commercially available as part of the next phase of Alzheimer’s Disease (AD) test development. The kit uses p-Tau 217 antibody technology...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2024
QTRX
LISTED
NASDAQ
Quanterix to Participate at the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will take part in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 at 1:50...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2024
QTRX
LISTED
NASDAQ
Jeffrey Elliott Appointed to Quanterix’s Board of Directors
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors.
Mr. Elliott brings two decades of senior leadership experience in the medical diagnostics industry, including 8 years a...
Themefolio
Profiler
Peergroup
© BusinessWire
08.08.2024
QTRX
LISTED
NASDAQ
Quanterix Releases Financial Results for the Second Quarter of 2024
News Preview
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2024.
“Our research business once again delivered strong performance in the second quarter, growing double digits,” said Masoud Toloue, Chief Executive O...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
